Skip to main content
Blog

Live healthier, stronger and sharper for longer

Short, frequent pieces on what changed in the science of ageing well — and our research library holds the deep dives.

Showing 12 of 513 posts Clear filters
CJC-1295: 2026’s Latest Evidence on Growth
Peptides
CJC-1295PeptidesGrowth Hormone

CJC-1295: 2026’s Latest Evidence on Growth

Dive into the newest 2026 evidence surrounding CJC-1295 with DAC, examining its role in growth hormone modulation, clinical efficacy, and safety profile.

Aug 23, 20269 min
CJC-1295: Latest 2026 Evidence and Revised
Peptides
CJC-1295PeptidesGrowth Hormone

CJC-1295: Latest 2026 Evidence and Revised

Dive into the cutting-edge research on CJC-1295, focusing on breakthroughs and revised recommendations emerging in 2026 for healthspan optimisation.

Aug 23, 20269 min
CJC-1295: Latest Clinical Evidence & Safety
Peptides
CJC-1295PeptidesGrowth Hormone

CJC-1295: Latest Clinical Evidence & Safety

Dive into the latest 2026 clinical evidence for CJC-1295 with DAC, examining its mechanisms, revised benefits, and safety considerations for healthspan optimisation.

Aug 22, 20269 min
CJC-1295 in 2026: Unpacking the Latest Evidence
Peptides
CJC-1295PeptidesGrowth Hormone

CJC-1295 in 2026: Unpacking the Latest Evidence

Dive into the cutting-edge research on CJC-1295 (with DAC) from 2025-2026, examining new clinical trials, revised recommendations, and its place in longevity strategies.

Aug 22, 20269 min
CJC-1295 & Sleep Architecture: Optimising
Peptides
CJC-1295SleepGrowth Hormone

CJC-1295 & Sleep Architecture: Optimising

CJC-1295, a long-acting GHRH analogue, is often discussed for muscle and recovery. This post delves into its specific, nuanced effects on sleep architecture.

Aug 17, 20269 min
CJC-1295 and Longevity Biomarkers: Outlook for
Peptides
CJC-1295PeptidesLongevity Biomarkers

CJC-1295 and Longevity Biomarkers: Outlook for

CJC-1295 is a synthetic GHRH analogue. This deep-dive examines its documented and speculative effects on critical longevity biomarkers, offering a scientific perspective for 2026.

Aug 15, 20269 min
CJC-1295 UK Availability & Cost: Navigating
Peptides
CJC-1295Peptides UKGrowth Hormone

CJC-1295 UK Availability & Cost: Navigating

Understanding CJC-1295 in the UK for 2026: legalities, sourcing, costs, and safety precautions for this growth hormone-releasing peptide.

Aug 15, 20269 min
CJC-1295's Metabolic & Glucose Impact:
Peptides
CJC-1295metabolic healthglucose regulation

CJC-1295's Metabolic & Glucose Impact:

CJC-1295, a synthetic GHRH analogue, holds potential for metabolic health, particularly in glucose regulation and body composition. We delve into the evidence.

Aug 14, 202612 min
CJC-1295 Ipamorelin Growth Hormone Safety: A
Peptides
CJC-1295IpamorelinGrowth Hormone

CJC-1295 Ipamorelin Growth Hormone Safety: A

CJC-1295 Ipamorelin is a popular peptide combination for growth hormone release. This review examines its safety, efficacy, and potential side effects.

Aug 7, 20268 min
CJC-1295 Stacks: Synergistic Longevity for 2026
Peptides
CJC-1295Peptide StacksGrowth Hormone

CJC-1295 Stacks: Synergistic Longevity for 2026

Discover how CJC-1295 can be strategically stacked with other compounds to amplify its benefits for longevity, focusing on cognitive function, recovery, and metabolic health.

Aug 7, 20269 min
CJC-1295 for Enhanced Cognition & Focus in
Peptides
CJC-1295Cognitive EnhancementNeuroplasticity

CJC-1295 for Enhanced Cognition & Focus in

CJC-1295, a GHRH analogue, is gaining traction for its potential cognitive benefits. We delve into the science of its impact on focus, memory, and neuroplasticity.

Aug 2, 20269 min
CJC-1295 After 50: Longevity Insights for 2026
Peptides
CJC-1295PeptidesAnti-Ageing

CJC-1295 After 50: Longevity Insights for 2026

CJC-1295, a GHRH analogue, holds potential for healthy ageing, particularly for those over 50. We dissect its benefits, risks, and responsible use.

Jul 30, 20269 min

Wondering where to start?

Two minutes, no blood test, no sign-up — find out how you are actually ageing, and what to do about it.

The Sunday briefing

One email a week: what changed in the evidence, what it means for the markers you track, and the occasional thing worth stopping. No spam, unsubscribe anytime.